Truist Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $54
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Srikripa Devarakonda maintains a Buy rating on Kymera Therapeutics (KYMR) and raises the price target from $41 to $54.
March 01, 2024 | 1:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities maintains a Buy rating on Kymera Therapeutics and raises the price target from $41 to $54.
The upgrade in price target by Truist Securities, a reputable financial institution, suggests a strong confidence in Kymera Therapeutics' future performance. This is likely to positively influence investor sentiment and potentially increase the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100